Meglumine antimoniate

Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]

Meglumine antimoniate
Clinical data
Other namesMeglumine antimonate
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
  • Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.004.645
Chemical and physical data
FormulaVariable
Molar massVariable
3D model (JSmol)
  • O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
  • InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 checkY
  • Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M checkY
 ☒NcheckY (what is this?)  (verify)

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines.[3] It is available in Southern Europe and Latin America but not the United States.[4][5]

Society and culture

It is manufactured by Aventis[6] and sold as Glucantime in France, and Glucantim in Italy.

See also

References
  1. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
  2. Sneader W (2005). "Chemical Medicines". Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
  3. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. Wolfe M (2010). "Antiparasitic Drugs". In Bope ET, Kellerman RD, Rakel RE (eds.). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20.
  5. Gorbach SL, Bartlett JG, Blacklow NR (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
  6. "Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" [Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income]. Aventis press release (in German). 15 April 2005. Archived from the original on 22 May 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.